Marek BęBenek
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Marek BęBenek has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Bartosz Kapturkiewicz
Department of Oncology and Haematology, Faculty of Medicine, Wroclaw University of Science and Technology, 50-370 Wroclaw, Poland
7 shared publications - Michał Kazanowski
Department of Oncology and Haematology, Faculty of Medicine, Wroclaw University of Science and Technology, 50-370 Wroclaw, Poland
7 shared publications - Paweł Lesiak
Department of Surgical Oncology, Pulmonology and Hematology, Lower Silesian Center of Oncology, Wrocław, Poland
7 shared publications - Jędrzej Wierzbicki
Department of Surgical Oncology, Lower Silesian Center of Oncology, Pulmonology and Hematology, Wroclaw, Poland, Hirszfeld Institute of Immunology & Experimental Therapy, Polish Academy of Sciences, Laboratory of Immunopathology, Department of Experimental Therapy, Wroclaw, Poland
3 shared publications - Damian Nowiński
Department of Minimally Invasive and Oncological General Surgery, Voivodeship Hospital in Bialystok, 15-950 Bialystok, Poland
2 shared publications - David Ramsey
Wroclaw University of Science and Technology
2 shared publications
Latest Publications
- Open Access
Preoperative CT Nodal Staging Versus Pathology in Colon Cancer: A Retrospective Multicentre Diagnostic Accuracy Study
Background/Objectives: Computed tomography (CT) informs preoperative staging in colon cancer, yet its diagnostic accuracy for lymph node involvement relative to pathological staging remains uncertain. We examined nodal concordance and multicentre variation in Poland. Methods: This retrospective diagnostic accuracy study included adults who underwent upfront resection for nonmetastatic colon cancer at five centres between January 2022 and August 2025. All underwent preoperative CT; recorded cN categories were dichotomised as cN0 versus cN+ (any positive cN category), and pathological pN was the reference. We estimated accuracy, sensitivity, specificity, predictive values, and kappa with 95% confidence intervals. A centre-adjusted exploratory analysis examined the association between cT3–4 and occult pN+ among cN0 patients. Results: Of 662 otherwise eligible patients, 590 had evaluable cN and pN. CT and pathology agreed in 386 (65.4%; 95% CI, 61.5–69.2; κ = 0.276; 95% CI, 0.199–0.353). Occult pN+ occurred in 73 of 335 cN0 patients (21.8%; 95% CI, 17.7–26.5); 131 of 255 cN+ patients were pN0 (51.4%; 95% CI, 45.3–57.4). Sensitivity was 62.9% and specificity 66.7%. Centre-level cN/pN completeness ranged from 73.5% to 100%. cT3–4 was associated with occult pN+ after centre adjustment (OR, 3.10; 95% CI, 1.71–5.62). Sensitivity analyses were materially consistent. Conclusions: Routine CT nodal classification showed limited concordance with pathology. The cT3–4 association is exploratory and does not establish a prediction or treatment selection rule; cN alone should not determine treatment.
Open AccessPreoperative CT Nodal Staging Versus Pathology in Colon Cancer: A Retrospective Multicentre Diagnostic Accuracy Study
Background/Objectives: Computed tomography (CT) informs preoperative staging in colon cancer, yet its diagnostic accuracy for lymph node involvement relative to pathological staging remains uncertain. We examined nodal concordance and multicentre variation in Poland. Methods: This retrospective diagnostic accuracy study included adults who underwent upfront resection for nonmetastatic colon cancer at five centres between January 2022 and August 2025. All underwent preoperative CT; recorded cN categories were dichotomised as cN0 versus cN+ (any positive cN category), and pathological pN was the reference. We estimated accuracy, sensitivity, specificity, predictive values, and kappa with 95% confidence intervals. A centre-adjusted exploratory analysis examined the association between cT3–4 and occult pN+ among cN0 patients. Results: Of 662 otherwise eligible patients, 590 had evaluable cN and pN. CT and pathology agreed in 386 (65.4%; 95% CI, 61.5–69.2; κ = 0.276; 95% CI, 0.199–0.353). Occult pN+ occurred in 73 of 335 cN0 patients (21.8%; 95% CI, 17.7–26.5); 131 of 255 cN+ patients were pN0 (51.4%; 95% CI, 45.3–57.4). Sensitivity was 62.9% and specificity 66.7%. Centre-level cN/pN completeness ranged from 73.5% to 100%. cT3–4 was associated with occult pN+ after centre adjustment (OR, 3.10; 95% CI, 1.71–5.62). Sensitivity analyses were materially consistent. Conclusions: Routine CT nodal classification showed limited concordance with pathology. The cT3–4 association is exploratory and does not establish a prediction or treatment selection rule; cN alone should not determine treatment.
- Open Access
- 6 September 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (17) , 6903
Clinical Burden of Anastomotic Leak After Elective Colorectal Cancer Surgery: A Multicenter Cohort Study
Background: Anastomotic leak remains a major complication after colorectal cancer surgery. While most studies focus on prediction or prevention, less is known about the clinical course after leak diagnosis. We aimed to evaluate the occurrence, severity, management, and early postoperative consequences of anastomotic leak after elective colorectal cancer surgery. Methods: This retrospective multicenter cohort study included consecutive patients undergoing elective colorectal cancer resection with restoration of bowel continuity in five tertiary referral centers. Patients without an evaluable anastomosis were excluded. The primary endpoint was 30-day anastomotic leak incidence. Secondary endpoints included Clavien–Dindo severity, therapeutic management, major morbidity, surgical reintervention, length of hospital stay, intensive care unit admission, readmission, and 30-day mortality. Firth penalized logistic regression was used for adjusted analyses. Results: Among 943 patients with an evaluable anastomosis, 55 developed an anastomotic leak (5.8%). Leak was more frequent after rectal than colon cancer surgery (8.8% vs. 4.5%; crude OR 2.04, 95% CI 1.18–3.53; p = 0.016). After adjustment, rectal cancer remained independently associated with leak occurrence (adjusted OR 3.61, 95% CI 1.74–7.48; p < 0.001), whereas intraoperative indocyanine green fluorescence angiography was not (adjusted OR 1.02, 95% CI 0.48–2.17; p = 0.962). Once leak occurred, 92.7% of patients developed major morbidity, 76.4% required surgical reintervention, and, among patients with available length-of-stay data, 65.4% had a postoperative hospital stay exceeding 14 days; 30-day mortality was 10.9%. Conclusions: Anastomotic leak occurred in fewer than 6% of elective colorectal cancer resections but was associated with severe postoperative deterioration. Its impact is better captured by evaluating severity, management, and downstream consequences, rather than incidence alone.
- 6 September 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (17) , 6903
Open AccessClinical Burden of Anastomotic Leak After Elective Colorectal Cancer Surgery: A Multicenter Cohort Study
Background: Anastomotic leak remains a major complication after colorectal cancer surgery. While most studies focus on prediction or prevention, less is known about the clinical course after leak diagnosis. We aimed to evaluate the occurrence, severity, management, and early postoperative consequences of anastomotic leak after elective colorectal cancer surgery. Methods: This retrospective multicenter cohort study included consecutive patients undergoing elective colorectal cancer resection with restoration of bowel continuity in five tertiary referral centers. Patients without an evaluable anastomosis were excluded. The primary endpoint was 30-day anastomotic leak incidence. Secondary endpoints included Clavien–Dindo severity, therapeutic management, major morbidity, surgical reintervention, length of hospital stay, intensive care unit admission, readmission, and 30-day mortality. Firth penalized logistic regression was used for adjusted analyses. Results: Among 943 patients with an evaluable anastomosis, 55 developed an anastomotic leak (5.8%). Leak was more frequent after rectal than colon cancer surgery (8.8% vs. 4.5%; crude OR 2.04, 95% CI 1.18–3.53; p = 0.016). After adjustment, rectal cancer remained independently associated with leak occurrence (adjusted OR 3.61, 95% CI 1.74–7.48; p < 0.001), whereas intraoperative indocyanine green fluorescence angiography was not (adjusted OR 1.02, 95% CI 0.48–2.17; p = 0.962). Once leak occurred, 92.7% of patients developed major morbidity, 76.4% required surgical reintervention, and, among patients with available length-of-stay data, 65.4% had a postoperative hospital stay exceeding 14 days; 30-day mortality was 10.9%. Conclusions: Anastomotic leak occurred in fewer than 6% of elective colorectal cancer resections but was associated with severe postoperative deterioration. Its impact is better captured by evaluating severity, management, and downstream consequences, rather than incidence alone.
- 1 July 2026
- Published by Index Copernicus in Polish Journal of Surgery
- Vol. 98 (4) , 1-13
Surgical Management of Low-Grade Appendiceal Mucinous Neoplasms: Evidence-Based Decision Algorithms for Cytoreductive Surgery and Surveillance
Introduction: Low-grade appendiceal mucinous neoplasm (LAMN) is a rare appendiceal tumor with indolent histology but a clinically relevant risk of peritoneal dissemination and pseudomyxoma peritonei, creating uncertainty in surgical extent and follow-up.Aim: To synthesize evidence on surgical decision-making in LAMN, including indications for right hemicolectomy, TNM interpretation, perforation management, imaging limitations, Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC) selection, and surveillance.Methods: A targeted narrative review was conducted using biomedical sources (2000–2026), supplemented by manual reference screening and citation tracking of key guidelines, consensus statements, and cohort studies. Evidence on pathology, staging, imaging, operative strategy, intraperitoneal treatment, and surveillance was narratively synthesized into clinical decision frameworks.Results: Contemporary evidence supports de-escalation for most localized LAMN. Routine right hemicolectomy is usually overtreatment in non-perforated pTis/pT3 disease after complete appendectomy and is not routinely indicated in selected perforated cases with acellular mucin. LAMN staging differs from adenocarcinoma, including absence of T1/T2 categories and prognostic distinction between M1a and M1b disease. Perforation increases recurrence risk and supports risk-adapted surveillance but does not alone mandate right hemicolectomy.Discussion: The evidence base remains predominantly retrospective and surveillance protocols are heterogeneous, limiting standardization.Conclusions: Risk-stratified, evidence-based algorithms can reduce overtreatment while preserving oncologic safety in LAMN.Significance of the study: This review integrates staging, operative strategy, and surveillance into a practical framework for standardized LAMN management and future multicenter research planning.
- 1 July 2026
- Published by Index Copernicus in Polish Journal of Surgery
- Vol. 98 (4) , 1-13
Surgical Management of Low-Grade Appendiceal Mucinous Neoplasms: Evidence-Based Decision Algorithms for Cytoreductive Surgery and Surveillance
Introduction: Low-grade appendiceal mucinous neoplasm (LAMN) is a rare appendiceal tumor with indolent histology but a clinically relevant risk of peritoneal dissemination and pseudomyxoma peritonei, creating uncertainty in surgical extent and follow-up.Aim: To synthesize evidence on surgical decision-making in LAMN, including indications for right hemicolectomy, TNM interpretation, perforation management, imaging limitations, Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC) selection, and surveillance.Methods: A targeted narrative review was conducted using biomedical sources (2000–2026), supplemented by manual reference screening and citation tracking of key guidelines, consensus statements, and cohort studies. Evidence on pathology, staging, imaging, operative strategy, intraperitoneal treatment, and surveillance was narratively synthesized into clinical decision frameworks.Results: Contemporary evidence supports de-escalation for most localized LAMN. Routine right hemicolectomy is usually overtreatment in non-perforated pTis/pT3 disease after complete appendectomy and is not routinely indicated in selected perforated cases with acellular mucin. LAMN staging differs from adenocarcinoma, including absence of T1/T2 categories and prognostic distinction between M1a and M1b disease. Perforation increases recurrence risk and supports risk-adapted surveillance but does not alone mandate right hemicolectomy.Discussion: The evidence base remains predominantly retrospective and surveillance protocols are heterogeneous, limiting standardization.Conclusions: Risk-stratified, evidence-based algorithms can reduce overtreatment while preserving oncologic safety in LAMN.Significance of the study: This review integrates staging, operative strategy, and surveillance into a practical framework for standardized LAMN management and future multicenter research planning.
- Open Access
- 31 March 2026
- Published by Springer Nature in Techniques in Coloproctology
- Vol. 30 (1)
Analysis of the impact of the learning curve and other factors on the duration of TaTME procedures
Background: Transanal total mesorectal excision (TaTME) is a technically demanding procedure with a significant learning curve. Operative time is often used as a proxy for procedural proficiency. Objective: To evaluate the impact of the learning curve and selected patient- and procedure-related factors on the operative duration of TaTME procedures. Methods: A retrospective analysis was conducted on 250 consecutive patients who underwent TaTME for rectal cancer between 2016 and 2025. Operative time trends were assessed in relation to case sequence, individual surgeon experience, and patient-related variables including sex, body mass index (BMI), ASA score, and technical aspects such as protective ileostomy creation. Results: The mean operative time across the cohort was 200.52 min. A significant reduction in operative duration was observed over time, with stabilizing after approximately 100 cases. Male sex, higher BMI, and ASA scores ≥ 3 were independently associated with longer operative times. The use of a protective ileostomy also significantly increased operative duration. After adjusting for surgeon experience and case complexity, no difference remained between laparoscopic and open approaches. Substantial interoperator variability was observed, particularly in early cases. Conclusions: TaTME is associated with a steep learning curve, which significantly increases operative time. Patient-related factors such as sex, BMI, and comorbidities further influence surgical duration. These findings support the need for structured training pathways, outcome monitoring, and individualized preoperative planning.
- 31 March 2026
- Published by Springer Nature in Techniques in Coloproctology
- Vol. 30 (1)
Open AccessAnalysis of the impact of the learning curve and other factors on the duration of TaTME procedures
Background: Transanal total mesorectal excision (TaTME) is a technically demanding procedure with a significant learning curve. Operative time is often used as a proxy for procedural proficiency. Objective: To evaluate the impact of the learning curve and selected patient- and procedure-related factors on the operative duration of TaTME procedures. Methods: A retrospective analysis was conducted on 250 consecutive patients who underwent TaTME for rectal cancer between 2016 and 2025. Operative time trends were assessed in relation to case sequence, individual surgeon experience, and patient-related variables including sex, body mass index (BMI), ASA score, and technical aspects such as protective ileostomy creation. Results: The mean operative time across the cohort was 200.52 min. A significant reduction in operative duration was observed over time, with stabilizing after approximately 100 cases. Male sex, higher BMI, and ASA scores ≥ 3 were independently associated with longer operative times. The use of a protective ileostomy also significantly increased operative duration. After adjusting for surgeon experience and case complexity, no difference remained between laparoscopic and open approaches. Substantial interoperator variability was observed, particularly in early cases. Conclusions: TaTME is associated with a steep learning curve, which significantly increases operative time. Patient-related factors such as sex, BMI, and comorbidities further influence surgical duration. These findings support the need for structured training pathways, outcome monitoring, and individualized preoperative planning.
- Open Access
- 4 March 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Incidence and risk factors for anastomotic leakage after transanal total mesorectal excision in a retrospective cohort of 212 patients
Anastomotic leakage remains a major complication in colorectal surgery. Although several risk factors have been identified, the specific risks associated with TaTME procedures require further clarification. The aim of this study was to determine the frequency of anastomotic leakage after TaTME and to identify factors influencing leakage rates. Out of 237 patients who underwent TaTME, 229 received an anastomosis. Seventeen were excluded from further analysis—14 due to lack of leakage assessment before ileostomy closure and 3 due to missing follow-up data—resulting in a final cohort of 212 patients. Cases were analysed with respect to anastomotic technique and other variables potentially affecting the incidence of anastomotic leakage. Data were obtained from a prospectively maintained institutional database. The mean tumour distance from the anorectal junction (ARJ) was 2.92 cm (± 1.56). Anastomotic leakage occurred in 27 patients (12.74%). The only statistically significant risk factor for leakage was the type of anastomosis: leakage occurred in 18.28% of patients with hand-sewn anastomosis and in 8.47% of those with stapled anastomosis. Tumour height indirectly influenced the leakage rate, as hand-sewn anastomosis was used predominantly in lower tumours (1.78 cm vs. 3.82 cm from the ARJ). Anastomotic leakage rates after TaTME are comparable to those reported for other rectal cancer surgical techniques. Leakage risk is primarily determined by the type of anastomosis and, indirectly, by tumour height. TaTME appears to be a feasible option for selected patients in experienced centres, although further validation is required.
- 4 March 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessIncidence and risk factors for anastomotic leakage after transanal total mesorectal excision in a retrospective cohort of 212 patients
Anastomotic leakage remains a major complication in colorectal surgery. Although several risk factors have been identified, the specific risks associated with TaTME procedures require further clarification. The aim of this study was to determine the frequency of anastomotic leakage after TaTME and to identify factors influencing leakage rates. Out of 237 patients who underwent TaTME, 229 received an anastomosis. Seventeen were excluded from further analysis—14 due to lack of leakage assessment before ileostomy closure and 3 due to missing follow-up data—resulting in a final cohort of 212 patients. Cases were analysed with respect to anastomotic technique and other variables potentially affecting the incidence of anastomotic leakage. Data were obtained from a prospectively maintained institutional database. The mean tumour distance from the anorectal junction (ARJ) was 2.92 cm (± 1.56). Anastomotic leakage occurred in 27 patients (12.74%). The only statistically significant risk factor for leakage was the type of anastomosis: leakage occurred in 18.28% of patients with hand-sewn anastomosis and in 8.47% of those with stapled anastomosis. Tumour height indirectly influenced the leakage rate, as hand-sewn anastomosis was used predominantly in lower tumours (1.78 cm vs. 3.82 cm from the ARJ). Anastomotic leakage rates after TaTME are comparable to those reported for other rectal cancer surgical techniques. Leakage risk is primarily determined by the type of anastomosis and, indirectly, by tumour height. TaTME appears to be a feasible option for selected patients in experienced centres, although further validation is required.
- 15 February 2026
- Published by Termedia Sp. z.o.o. in Archives of Medical Science
Combined CRS-HIPEC for Peritoneal Malignancies: A 10-Year Single-Center Experience
Introduction: Peritoneal surface malignancies (PSMs) are challenging to treat due to their locoregional nature and poor response to systemic therapies. Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has emerged as a promising treatment for selected patients, though long-term, real-world data remain limited. Aim of the study: To analyze clinical outcomes, survival patterns, and prognostic factors in a large cohort of patients undergoing CRS-HIPEC over a 10-year period at a national referral center. Material and methods: This retrospective study included 292 adult patients who underwent 319 CRS-HIPEC procedures between 2015 and 2024. Primary endpoints included overall survival (OS) and postoperative outcomes. Data were stratified by tumor type, Peritoneal Cancer Index (PCI), and Completeness of Cytoreduction (CC-score). Results: The most common indications were colorectal cancer (34.5%), ovarian cancer (27.0%), low-grade appendiceal mucinous neoplasm (LAMN) (16.1%), primary peritoneal cancer (17.7%), and gastric cancer (3.7%). Complete cytoreduction (CC-0) was achieved in 69.9% of cases. Five-year survival rates were highest in LAMN (90.4%) and primary peritoneal cancer (80.7%), and lowest in gastric cancer (25.0%). Lower PCI (<20) and CC-0 resection were strongly associated with improved survival. Postoperative morbidity declined over time, with no in-hospital mortality since 2022. Conclusions: CRS-HIPEC offers substantial long-term survival benefits in selected patients with PSMs. Tumor biology, PCI, and completeness of cytoreduction are key prognostic factors. Our findings support expanding access to HIPEC in well-selected cases, particularly in tumors with peritoneal-confined dissemination.
- 15 February 2026
- Published by Termedia Sp. z.o.o. in Archives of Medical Science
Combined CRS-HIPEC for Peritoneal Malignancies: A 10-Year Single-Center Experience
Introduction: Peritoneal surface malignancies (PSMs) are challenging to treat due to their locoregional nature and poor response to systemic therapies. Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has emerged as a promising treatment for selected patients, though long-term, real-world data remain limited. Aim of the study: To analyze clinical outcomes, survival patterns, and prognostic factors in a large cohort of patients undergoing CRS-HIPEC over a 10-year period at a national referral center. Material and methods: This retrospective study included 292 adult patients who underwent 319 CRS-HIPEC procedures between 2015 and 2024. Primary endpoints included overall survival (OS) and postoperative outcomes. Data were stratified by tumor type, Peritoneal Cancer Index (PCI), and Completeness of Cytoreduction (CC-score). Results: The most common indications were colorectal cancer (34.5%), ovarian cancer (27.0%), low-grade appendiceal mucinous neoplasm (LAMN) (16.1%), primary peritoneal cancer (17.7%), and gastric cancer (3.7%). Complete cytoreduction (CC-0) was achieved in 69.9% of cases. Five-year survival rates were highest in LAMN (90.4%) and primary peritoneal cancer (80.7%), and lowest in gastric cancer (25.0%). Lower PCI (<20) and CC-0 resection were strongly associated with improved survival. Postoperative morbidity declined over time, with no in-hospital mortality since 2022. Conclusions: CRS-HIPEC offers substantial long-term survival benefits in selected patients with PSMs. Tumor biology, PCI, and completeness of cytoreduction are key prognostic factors. Our findings support expanding access to HIPEC in well-selected cases, particularly in tumors with peritoneal-confined dissemination.
- Open Access
Peritoneal Cancer Index Dominates Prognosis After CRS–HIPEC for Colorectal Peritoneal Metastases: A Consecutive Single-Centre Cohort with 3-Year Follow-Up
Background: Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) can cure selected patients with colorectal peritoneal metastases (CPM). Real-world prognostic data, especially for the Peritoneal Cancer Index (PCI) and completeness of cytoreduction (CCR), are limited. Methods: We retrospectively analysed 75 consecutive patients treated with CRS + HIPEC at a tertiary centre (2014–2022), giving ≥36 months potential follow-up. Overall survival (OS) was assessed by Kaplan–Meier and Cox models. PCI was grouped 0–10, 11–20, >20; CCR was dichotomised (CCR-0 vs. CCR 1/2). Multivariable analysis included PCI, CCR, and resection extent; HIPEC drug was examined univariately. Results: The median follow-up was 41 months. Crude 3-year OS was 50.7% (38/75). Survival decreased with higher PCI: 69% for 0–10 (n = 42), 38% for 11–20 (n = 21), and 0% for > 20 (n = 4). Versus PCI 0–10, the adjusted hazard ratios (HR) were 3.02 (95% CI 1.52–6.03) for PCI 11–20 and 7.29 (1.72–30.81) for > 20. CCR-0 improved OS univariately (HR 0.43) but was non-significant after adjustment (HR 0.89). Resection limited to the peritoneum (HR 0.99) and choice of intraperitoneal drug showed no independent effect. Conclusions: In this real-world cohort, PCI was the only independent predictor of 3-year survival after CRS + HIPEC for CPM; neither CCR status, surgical extent, nor HIPEC agent altered prognosis once PCI was considered. PCI should therefore remain the principal selection criterion while molecular and biological markers are integrated into future risk models.
Open AccessPeritoneal Cancer Index Dominates Prognosis After CRS–HIPEC for Colorectal Peritoneal Metastases: A Consecutive Single-Centre Cohort with 3-Year Follow-Up
Background: Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) can cure selected patients with colorectal peritoneal metastases (CPM). Real-world prognostic data, especially for the Peritoneal Cancer Index (PCI) and completeness of cytoreduction (CCR), are limited. Methods: We retrospectively analysed 75 consecutive patients treated with CRS + HIPEC at a tertiary centre (2014–2022), giving ≥36 months potential follow-up. Overall survival (OS) was assessed by Kaplan–Meier and Cox models. PCI was grouped 0–10, 11–20, >20; CCR was dichotomised (CCR-0 vs. CCR 1/2). Multivariable analysis included PCI, CCR, and resection extent; HIPEC drug was examined univariately. Results: The median follow-up was 41 months. Crude 3-year OS was 50.7% (38/75). Survival decreased with higher PCI: 69% for 0–10 (n = 42), 38% for 11–20 (n = 21), and 0% for > 20 (n = 4). Versus PCI 0–10, the adjusted hazard ratios (HR) were 3.02 (95% CI 1.52–6.03) for PCI 11–20 and 7.29 (1.72–30.81) for > 20. CCR-0 improved OS univariately (HR 0.43) but was non-significant after adjustment (HR 0.89). Resection limited to the peritoneum (HR 0.99) and choice of intraperitoneal drug showed no independent effect. Conclusions: In this real-world cohort, PCI was the only independent predictor of 3-year survival after CRS + HIPEC for CPM; neither CCR status, surgical extent, nor HIPEC agent altered prognosis once PCI was considered. PCI should therefore remain the principal selection criterion while molecular and biological markers are integrated into future risk models.
- 1 March 2015
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 114 (3) , 302-309
Selection of appropriate end-points (pCR vs 2yDFS) for tailoring treatments with prediction models in locally advanced rectal cancer
- 1 March 2015
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 114 (3) , 302-309
Selection of appropriate end-points (pCR vs 2yDFS) for tailoring treatments with prediction models in locally advanced rectal cancer